Vertebral Technologies, Inc. (VTI) Announces New President & CEO

Minneapolis, MN, September 25, 2015 (Newswire.com) - The Board of Directors of Vertebral Technologies, Inc. is happy to announce the appointment of Matthew R. Kyle as President and Chief Executive Officer of the Company effective May 1, 2015.  Mr. Kyle succeeds Dr. Jeffery Felt, Founder and CEO, who will continue with the company in the role of Chief Technology Officer. 

 Mr. Kyle comes to VTI from outside the company and plans to streamline and focus company operations toward commercial growth. After serving as President and Corporate Counsel for Millennium Medical, Matt co-founded Circle Biologics where he served as President and CEO.  Circle Biologics developed a unique core technology for harvesting various specialized cells (including stem cells) from patients and delivering the cells back to the patient’s specific areas of need.  Matt grew the company from concept to a successful exit in late 2014.  He brings high integrity and a great work ethic, along with excellent management skills and experience to the CEO position. 

"I am excited by our technology's ability to reproducibly deliver 'expandability' in the clinical setting. At a time when competitors are offering new complicated-, mechanical- solutions to achieve implant expandability, VTI's systems stand alone in 1) their proven track record of 5,000+ successful cases to date and 2) their clinical design rational."

Matthew Kyle, President and CEO

 “VTI’s technology suite is impressive and increasingly relevant in today’s spine market as surgeon and payer interest in less invasive approaches with sound biomechanical, clinical, and patient adaptability foundations increase. VTI’s modular technology platform differentiates itself from competitive products in its ability to deliver a large, load bearing surface with patient adaptability through a design form that facilitates reproducibility at the clinical level.” said Mr. Kyle. “I am excited by our technology’s ability to reproducibly deliver ‘expandability’ in the clinical setting. At a time when competitors are offering new complicated-, mechanical- solutions to achieve implant expandability, VTI’s systems stand alone in 1) their proven track record of 5,000+ successful cases to date and 2) their clinical design rational.”

Dr. Jeff Felt will continue with VTI as its Chief Technology Officer. In his new role Dr. Felt will continue to pursue VTI’s motion preserving spinal implant, the InterCushion, and raise awareness of the company’s unique modular technology suite through focused engagement with clinicians. ”I’m excited about the future of VTI. I will continue to be engaged in areas for which I have passion and expertise.  My role as CTO will allow me to focus additional efforts highlighting the clinical benefits of VTI's technology” said Dr. Felt.